Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
FISCHER

Fischer Medical Ventures Share Price

 

 

Fischer Medical Ventures live price: ₹37.13. It opened at ₹38 vs previous close ₹38; intraday high/low: ₹38/₹37. The 50 DMA stands at ₹39.70.

Fischer Medical Ventures Performance

  • Today's Low
  • ₹37
  • Today's High
  • ₹38
  • 52 Week Low
  • ₹32
  • 52 Week High
  • ₹125
  • Open Price₹38
  • Previous Close₹38
  • Volume924,968
  • 50 DMA₹39.70
  • 100 DMA₹47.25
  • 200 DMA-

Fischer Medical Ventures Chart

Investment Returns

  • Over 1 Month + 5.09%
  • Over 3 Month + 3.95%
  • Over 6 Month -64.36%
  • Over 1 Year -54.43%

Smart Investing Starts Here Start SIP with Fischer Medical Ventures for Steady Growth!

Invest Now

Fischer Medical Ventures Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 2,408
  • P/B Ratio
  • 6.3
  • Average True Range
  • 1.86
  • EPS
  • 0.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.49
  • RSI
  • 41.57
  • MFI
  • 47

Fischer Medical Ventures Financials

Fischer Medical Ventures Technicals

EMA & SMA

Current Price
₹37.13
-0.4 (-1.07%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 0
  • 20 Day
  • ₹38.99
  • 50 Day
  • ₹39.70
  • 100 Day
  • ₹47.25
  • 200 Day
  • -

Resistance and Support

37.21 Pivot Speed
  • R3 38.62
  • R2 38.18
  • R1 37.65
  • S1 36.68
  • S2 36.24
  • S3 35.71

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Fischer Medical Ventures Ltd has an operating revenue of Rs. 260.02 Cr. on a trailing 12-month basis. An annual revenue growth of 422% is outstanding, Pre-tax margin of 2% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 76 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Fischer Medical Ventures Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-30 Quarterly Results
2025-10-28 Quarterly Results & Others To consider other business matters split from Rs. 10/- to Re. 1/-.
2025-08-14 Quarterly Results & A.G.M.
2025-07-28 Stock Split
2025-05-28 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-12 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Fischer Medical Ventures F&O

Fischer Medical Ventures Shareholding Pattern

62.15%
0%
4.97%
24.92%
7.96%

Fischer Medical Ventures FAQs

Fischer Medical Ventures share price is ₹37 As on 25 April, 2026 | 16:38

The Market Cap of Fischer Medical Ventures is ₹2407.9 Cr As on 25 April, 2026 | 16:38

The P/E ratio of Fischer Medical Ventures is 61 As on 25 April, 2026 | 16:38

The PB ratio of Fischer Medical Ventures is 6.3 As on 25 April, 2026 | 16:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23